TIMI 55 REVEAL*
Randomized Evaluation of the Effects of Anaceptrapib through Lipid-modification Long Term Follow Up Trial
This trial is a follow up to the REVEAL TRIAL that involved over 30,000 men and women participants who had pre-existing vascular disease (such as history of heart attack or stroke). Participants were recruited from more than 400 hospitals in the United Kingdom, United States, Canada, China, Germany, Italy and Scandinavia.
The purpose of the study was to test if anacetrapib, a Cholesteryl Ester Transfer Protein (CETP) inhibitor, lowered the risk of heart attack and related cardiovascular complications for patients who were already receiving a statin, the standard of care treatment.
In the study, each participant took either 100 mg of anacetrapib or the inactive tablet (placebo) once daily.
Wherever possible, extended follow-up of all surviving and consenting randomized participants will continue for several years after the main study visit in order to provide valuable information on the longer-term effects of Anacetrapib. During this time, participants will not receive any study medication. There will be a particular focus on clinical safety, including cause-specific mortality, cancer, and vascular events. Information on other reasons for hospitalization and other serious adverse events will be collected whenever feasible. Follow-up will be by telephone.
Pooja S. Rajeevan, CRC; 425.635.6081; Pooja.Rajeevan@overlakehospital.org
Clinical Trial Categories
* Note: This trial is no longer recruiting new patients.